CY1119794T1 - Ενωσεις αναστολεων ε-σελεκτινης - Google Patents

Ενωσεις αναστολεων ε-σελεκτινης

Info

Publication number
CY1119794T1
CY1119794T1 CY20181100060T CY181100060T CY1119794T1 CY 1119794 T1 CY1119794 T1 CY 1119794T1 CY 20181100060 T CY20181100060 T CY 20181100060T CY 181100060 T CY181100060 T CY 181100060T CY 1119794 T1 CY1119794 T1 CY 1119794T1
Authority
CY
Cyprus
Prior art keywords
selectin
inhibiting
treatment
prevention
methods
Prior art date
Application number
CY20181100060T
Other languages
Greek (el)
English (en)
Inventor
John L. Magnani
Arun K. Sarkar
Myung-Gi Baek
Frank E. ANDERSON, III
Yanhong Li
Original Assignee
Glycomimetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics, Inc. filed Critical Glycomimetics, Inc.
Publication of CY1119794T1 publication Critical patent/CY1119794T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK  ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
    • C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
    • C09C1/62—Metallic pigments or fillers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20181100060T 2011-12-22 2018-01-17 Ενωσεις αναστολεων ε-σελεκτινης CY1119794T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161579646P 2011-12-22 2011-12-22
US201261583547P 2012-01-05 2012-01-05
US201261704424P 2012-09-21 2012-09-21
US201261704399P 2012-09-21 2012-09-21
US201261734924P 2012-12-07 2012-12-07
PCT/US2012/071519 WO2013096926A1 (en) 2011-12-22 2012-12-21 E-selectin antagonist compounds, compositions, and methods of use

Publications (1)

Publication Number Publication Date
CY1119794T1 true CY1119794T1 (el) 2018-06-27

Family

ID=48669591

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100060T CY1119794T1 (el) 2011-12-22 2018-01-17 Ενωσεις αναστολεων ε-σελεκτινης

Country Status (17)

Country Link
US (6) US9109002B2 (enExample)
EP (2) EP2794626B3 (enExample)
JP (5) JP2015500887A (enExample)
KR (1) KR102055958B1 (enExample)
CN (1) CN104039805B (enExample)
AU (1) AU2012358150B2 (enExample)
BR (1) BR112014014547B1 (enExample)
CA (1) CA2858099C (enExample)
CY (1) CY1119794T1 (enExample)
DK (1) DK2794626T6 (enExample)
ES (1) ES2655443T7 (enExample)
HU (1) HUE036253T2 (enExample)
LT (1) LT2794626T (enExample)
PL (1) PL2794626T6 (enExample)
PT (1) PT2794626T (enExample)
SI (1) SI2794626T1 (enExample)
WO (1) WO2013096926A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
EP2914610A2 (en) * 2012-10-31 2015-09-09 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
PT2928476T (pt) * 2012-12-07 2018-05-10 Glycomimetics Inc Compostos, composições e métodos que utilizam antagonistas de e-selectina para mobilização de células hematopoiéticas
CA2925119A1 (en) * 2013-09-30 2015-04-02 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
DE102013112915A1 (de) 2013-11-22 2015-05-28 Universitätsklinikum Hamburg-Eppendorf (UKE) DNA-Aptamere, die E- und P-Selektine spezifisch binden
US20160333043A1 (en) * 2014-01-17 2016-11-17 Glycomimetics, Inc. E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose
WO2016089872A1 (en) * 2014-12-03 2016-06-09 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2016164394A1 (en) * 2015-04-08 2016-10-13 Glycomimetics, Inc. 2-halo-galactose-containing selectin antagonists
US20160331775A1 (en) * 2015-05-14 2016-11-17 The Regents Of The University Of Michigan E-selectin inhibition works in combination with low-molecular weight heparin to decrease venous thrombosis and bleeding risk
US9891811B2 (en) * 2015-06-07 2018-02-13 Apple Inc. Devices and methods for navigating between user interfaces
EP3370724A2 (en) 2015-11-03 2018-09-12 GlycoMimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) * 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
BR112020013198A2 (pt) 2017-12-29 2020-12-01 Glycomimetics, Inc. inibidores heterobifuncionais de e-selectina e galectina-3
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
EP3893936A2 (en) 2018-12-10 2021-10-20 GlycoMimetics, Inc. Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2020150263A1 (en) 2019-01-14 2020-07-23 Magnani John L Selectin or galectin antagonists for treating cytokine release syndrome and crs-induced neurotoxicity
CA3136661A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
US20220220144A1 (en) 2019-04-24 2022-07-14 Glycomimetics, Inc. Multimeric pan-selectin antagonists
CN114341368A (zh) 2019-07-12 2022-04-12 糖模拟物有限公司 使用基因表达作为多种肿瘤类型的e-选择素抑制剂功效和临床结果的指标的方法
EP4003364A1 (en) 2019-07-31 2022-06-01 GlycoMimetics, Inc. Use of highly potent multimeric e-selectin antagonists for treating sickle cell disease
CA3146048A1 (en) 2019-07-31 2021-02-04 Glycomimetics, Inc. Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hosts
WO2021034796A1 (en) 2019-08-20 2021-02-25 Glycomimetics, Inc. Process for preparing an e-selectin inhibitor intermediate
US20230147312A1 (en) * 2020-03-27 2023-05-11 Glycomimetics, Inc. Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
WO2021247396A1 (en) 2020-05-31 2021-12-09 Magnani John L Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
MX2022015894A (es) * 2020-06-14 2023-01-24 Glycomimetics Inc Composiciones y metodos para superar la resistencia mediada por microentorno mediante direccionamiento de e-selectina.
WO2022061168A1 (en) * 2020-09-17 2022-03-24 Glycomimetics, Inc. E-selectin targeting agents
CN117120452A (zh) 2021-02-18 2023-11-24 糖模拟物有限公司 用于制备e-选择素抑制剂中间体的方法
US20240269157A1 (en) 2021-08-03 2024-08-15 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7409399A (nl) 1973-07-19 1975-01-21 Rhone Poulenc Sa Werkwijze ter bereiding van thermostabiele har- sen en voorwerpen geheel of gedeeltelijk be- staande uit deze harsen.
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
DK17885D0 (da) 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4876199A (en) 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US4851511A (en) 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
EP0249008B1 (de) 1986-05-09 1993-09-15 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
EP0381310A1 (en) 1989-01-30 1990-08-08 The Biomembrane Institute Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0583799A1 (en) 1989-05-23 1994-02-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to ELAM-1 sialoglycoprotein antigen on the surface of activated endothelial cells
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
WO1991019501A1 (en) 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU660627B2 (en) 1990-07-17 1995-07-06 Board Of Regents Of The University Of Oklahoma, The Functionally active selectin-derived peptide for GMP-140
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5143712A (en) 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5648344A (en) 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
NZ240316A (en) 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
HUT64476A (en) 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
DK0584229T3 (da) 1991-05-06 2003-11-17 Genentech Inc Glycam-1(Sgp 50), en selektinligand
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5646123A (en) 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
JPH07507040A (ja) 1991-09-10 1995-08-03 セントコー，インコーポレイテッド セレクチンによって介在される炎症のペプチド阻害剤
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5268364A (en) 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
AU3914393A (en) 1991-12-18 1994-03-15 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation mediated by selectins
US5591835A (en) 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
US5753617A (en) 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
AU4859793A (en) 1992-09-11 1994-04-12 Regents Of The University Of California, The Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
AU678429B2 (en) 1992-12-29 1997-05-29 Genentech Inc. Treatment of inflammatory bowel disease with IFN-gamma inhibitors
US5412123A (en) 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
JP2716657B2 (ja) 1993-02-26 1998-02-18 株式会社ディ・ディ・エス研究所 接着分子ｅｌａｍ‐１に特異的結合能を有する化合物
CA2157489A1 (en) 1993-03-04 1994-09-15 Masaaki Numata Lewis-associated compound, process for producing the same, and anti-inflammatory
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
CA2162478A1 (en) 1993-05-14 1994-11-24 Shawn A. Defrees Sialyl lex analogues as inhibitors of cellular adhesion
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
SE9301677L (sv) 1993-05-14 1994-11-18 Kurt G I Nilsson Syntesmetod
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
WO1994026786A1 (en) 1993-05-17 1994-11-24 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5750508A (en) 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
DK76193D0 (da) 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
US5827837A (en) 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
EP0671409A3 (de) 1994-03-11 1996-06-12 Hoechst Ag Malonsäurederivate mit antiadhäsiven Eigenschaften.
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
HUT77345A (hu) 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
US5444050A (en) * 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5486536A (en) 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (ja) 1994-09-30 1996-04-16 Akira Hasegawa 新規糖脂質誘導体およびその製造用中間体
DE4436164A1 (de) 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
MX9704893A (es) 1994-12-28 1997-10-31 Sumitomo Pharma Derivados de lewis x y procesos para producir los mismos.
US20020040008A1 (en) 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5527936A (en) 1995-02-17 1996-06-18 E. I. Du Pont De Nemours And Company Hydrosilylation of unsaturated compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
BR9609285A (pt) 1995-06-29 1999-05-11 Novartis Ag Dióis-1,2 diglicosilados como miméticos do sialil-lewis x e do sialil-lewis a
HU224590B1 (hu) 1995-06-29 2005-11-28 Texas Biotechnology Corporation Két- és háromértékű, kis molekulájú szelektin inhibitorok
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (de) 1995-09-06 1997-03-13 Hoechst Ag Neuartige Glycomimetika als Selektin-Antagonisten und daraus hergestellte entzündungshemmend wirkende Arzneimittel
DE19537334A1 (de) 1995-10-09 1997-04-10 Hoechst Ag Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren
AU7445796A (en) 1995-10-18 1997-05-07 Cytel Corporation Sialyl lex analogues as inhibitors of cellular adhesion
EP0859005A1 (en) 1995-10-26 1998-08-19 Kanebo, Ltd. Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
JPH09176047A (ja) 1995-12-25 1997-07-08 Unitika Ltd 外用医薬製剤
DE19602355A1 (de) 1996-01-24 1997-07-31 Hoechst Ag Mehrfach fucosylierte Dicarbonsäuren mit antiadhäsiven Eigenschaften
DE69737496D1 (de) 1996-01-30 2007-05-03 Glycomimetics Inc SIALYL-LEWISa UND SIALYL LEWISx EPITOP-ANALOGE
ATE397005T1 (de) 1996-01-30 2008-06-15 Glycomimetics Inc Sialyl-lewisa und sialyl-lewisx epitope analoge
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
CA2247115C (en) 1996-03-01 2008-11-18 The Regents Of The University Of California Inhibition of selectin binding
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
US5994402A (en) 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
US5919768A (en) 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
JP2000516224A (ja) 1996-08-08 2000-12-05 ノバルティス アクチエンゲゼルシャフト 修飾オリゴサッカライド
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
US6592872B1 (en) 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
ES2285740T3 (es) 1996-09-27 2007-11-16 The Trustees Of Columbia University In The City Of New York Tratamiento de un trastorno isquemico y mejora de las consecuencias de un accidente cerebrovascular.
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
WO1998037902A1 (en) 1997-02-28 1998-09-03 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes
JP3720520B2 (ja) 1997-03-27 2005-11-30 タカラバイオ株式会社 糖と標的物との相互作用の測定方法
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999043356A1 (en) 1998-02-25 1999-09-02 Hsc Research Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6458777B1 (en) 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6037333A (en) 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
AU773542B2 (en) 1998-06-16 2004-05-27 Board Of Regents Of The University Of Oklahoma, The Glycosulfopeptides and methods of synthesis and use thereof
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
CA2344652C (en) 1998-09-21 2007-11-20 Otsuka Pharmaceutical Co., Ltd. Carboxymethylgalactose derivatives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1131106B1 (en) 1998-11-12 2009-06-24 Novolytics Inc. Compositions and methods for producing vascular occlusion
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US20020031508A1 (en) 2000-05-19 2002-03-14 Wagner Denisa D. Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
AU2000274809A1 (en) 2000-09-12 2002-03-26 Genetics Institute Llc Inhibition of stenosis or restenosis by p-selectin antagonists
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2428721A1 (en) 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
AU2002251678A1 (en) 2000-11-29 2002-08-19 Bracco International B.V. Linkable sialyl lewis x analogs
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
CN101694497B (zh) 2001-03-28 2014-11-26 哈佛大学校长及研究员协会 将外源蛋白递送到胞质溶胶中的方法，及其用途
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
IL161784A0 (en) 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030186942A1 (en) 2002-01-16 2003-10-02 Crooks Peter A. Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
CA2490703A1 (en) 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
WO2004033663A2 (en) 2002-10-11 2004-04-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Carbohydrate-based synthetic vaccines for hiv
AU2003301209A1 (en) 2002-12-20 2004-07-22 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
US6844125B2 (en) 2003-03-20 2005-01-18 Kabushiki Kaisha Toshiba Combination of developing agents, image forming apparatus, and method for forming image
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20040219158A1 (en) 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
JP2007510735A (ja) 2003-11-07 2007-04-26 ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Ｃｄ４４グリコフォームに対する抗体およびその使用
DE602004011272T2 (de) 2003-11-19 2008-12-24 Glycomimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
CA2546784A1 (en) 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
DK1709063T3 (da) 2003-12-18 2008-06-02 Unibioscreen Sa Glycosyleret steroidderivat med anti-migratorisk aktivitet
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
US7745421B2 (en) 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
JP2008504531A (ja) 2004-06-24 2008-02-14 ザ スクリップス リサーチ インスティテュート 切断可能なリンカーを有するアレイ
WO2006017180A2 (en) 2004-07-09 2006-02-16 Progenics Pharmaceuticals, Inc. Glycopeptide dimers and uses thereof
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006062946A2 (en) 2004-12-06 2006-06-15 University Of Florida Research Foundation, Inc. Incorporation of bone marrow derived stem cells in tumors
CA2593578C (en) 2005-01-07 2013-11-05 Emory University Cxcr4 antagonists for the treatment of medical disorders
EP1838321A4 (en) 2005-01-07 2009-03-18 Univ Emory CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
WO2006127906A1 (en) 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
US20060287253A1 (en) 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
DK1928892T3 (da) 2005-08-09 2012-01-30 Glycomimetics Inc Glycomimetiske inhibitorer af PA-IL-lectin PA-IIL-lectin eller begge lectiner fra pseudomonas
RU2008105806A (ru) 2005-08-15 2009-09-27 Зе Скрипс Ресеч Инститьют (Us) Способы выявления терапевтических агентов
WO2007022385A2 (en) 2005-08-18 2007-02-22 Novartis Ag Use of cxcr4 binding molecules for the treatment of whim syndrome
PL1934236T3 (pl) 2005-09-02 2013-04-30 Glycomimetics Inc Heterobifunkcjonalne inhibitory pan-selektyny
CA2663633A1 (en) 2005-09-14 2007-03-22 Lai-Xi Wang Synthetic polyvalent carbohydrates as components of microbicides
EP2029164B1 (en) 2006-06-07 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
WO2008008852A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
CA2666103C (en) 2006-10-12 2014-02-18 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US20080306098A1 (en) 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2008100453A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
US20090054334A1 (en) 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
CN101918041A (zh) 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
US9486497B2 (en) 2007-12-10 2016-11-08 The University Of Queensland Treatment of immunocompromised conditions
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
US20100240773A1 (en) 2009-03-23 2010-09-23 Kenneth Korzekwa Multifunctional linkers
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012047918A1 (en) 2010-10-04 2012-04-12 Glycomimetics, Inc. Anti-epileptogenic agents
WO2012061662A1 (en) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
TWI497333B (zh) 2011-06-14 2015-08-21 Giant Mfg Co Ltd 自行車適配產生方法、自行車適配系統與電腦程式產品
WO2013096926A1 (en) * 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9104666B2 (en) 2012-09-04 2015-08-11 Oracle International Corporation Controlling access to a large number of electronic resources
PT2928476T (pt) * 2012-12-07 2018-05-10 Glycomimetics Inc Compostos, composições e métodos que utilizam antagonistas de e-selectina para mobilização de células hematopoiéticas
KR20200128025A (ko) * 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법

Also Published As

Publication number Publication date
JP2018035166A (ja) 2018-03-08
ES2655443T3 (es) 2018-02-20
EP2794626A1 (en) 2014-10-29
US20210017215A1 (en) 2021-01-21
JP2016020392A (ja) 2016-02-04
EP2794626B1 (en) 2017-11-01
HUE036253T2 (hu) 2018-06-28
JP2015500887A (ja) 2015-01-08
US10766916B2 (en) 2020-09-08
US20180066006A1 (en) 2018-03-08
DK2794626T3 (en) 2018-01-02
US10526361B2 (en) 2020-01-07
KR102055958B1 (ko) 2019-12-13
ES2655443T7 (es) 2021-03-22
AU2012358150B2 (en) 2017-07-20
DK2794626T6 (da) 2020-08-24
BR112014014547A2 (pt) 2017-06-13
US9796745B2 (en) 2017-10-24
US11332491B2 (en) 2022-05-17
JP6366150B2 (ja) 2018-08-01
HK1201842A1 (en) 2015-09-11
US11987598B2 (en) 2024-05-21
AU2012358150A1 (en) 2014-08-07
EP3296310A1 (en) 2018-03-21
PL2794626T3 (pl) 2018-06-29
JP2017210495A (ja) 2017-11-30
CA2858099A1 (en) 2013-06-27
US20230097694A1 (en) 2023-03-30
CN104039805B (zh) 2016-11-16
LT2794626T (lt) 2018-02-12
SI2794626T1 (en) 2018-02-28
US20150110808A1 (en) 2015-04-23
EP2794626B3 (en) 2020-08-05
BR112014014547B1 (pt) 2022-09-27
PT2794626T (pt) 2018-01-12
NZ627068A (en) 2016-09-30
US20160145290A1 (en) 2016-05-26
KR20140108285A (ko) 2014-09-05
CA2858099C (en) 2020-12-15
US9109002B2 (en) 2015-08-18
CN104039805A (zh) 2014-09-10
WO2013096926A1 (en) 2013-06-27
US20200157134A1 (en) 2020-05-21
PL2794626T6 (pl) 2020-11-02
JP2019048891A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
CY1119794T1 (el) Ενωσεις αναστολεων ε-σελεκτινης
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1123883T1 (el) Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1121460T1 (el) Διαμορφωση του μεταγωγεα σηματος και του ενεργοποιητη εκφρασης της μεταγραφης 3 (stat3)
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CY1124292T1 (el) Συνθεσεις για τροποποιηση της εκφρασης tau
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1116886T1 (el) C-met αντισωματα
CY1122156T1 (el) Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1117423T1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1119714T1 (el) Ενωσεις αναστολεων
CY1115502T1 (el) Παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1119199T1 (el) Αναστολεις cdc7
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα